

Edgar Filing: Adamas Pharmaceuticals Inc - Form 8-K

Adamas Pharmaceuticals Inc
Form 8-K
March 24, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2016

Adamas Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-36399 (Commission File Number)	42-1560076 (IRS Employer Identification No.)
---	---------------------------------------	---

1900 Powell Street, Suite 750

Emeryville, CA (Address of principal executive offices)	94608 (Zip Code)
--	---------------------

Registrant's telephone number, including area code: (510) 450-3500

Edgar Filing: Adamas Pharmaceuticals Inc - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 22, 2016, Sara Grootwassink Lewis, a director of Adamas Pharmaceuticals, Inc., advised Adamas Pharmaceuticals that she would not be standing for reelection as a director at Adamas Pharmaceuticals' upcoming annual meeting of stockholders. Effective on June 1, 2016, Richard Booth will become, and Ms. Lewis will cease to be, a member of the Adamas Pharmaceuticals Audit Committee. Effective at the annual meeting the size of the Adamas Pharmaceuticals Board of Directors will be reduced from eight to seven members.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Adamas
Pharmaceuticals, Inc.
Dated: March 24, 2016

By: /s/ Gregory T. Went
Gregory T. Went, Ph.D.
Chief Executive Officer and Chairman of the Board